![Factor XIII and the clotting of fibrinogen: from basic research to medicine - Journal of Thrombosis and Haemostasis Factor XIII and the clotting of fibrinogen: from basic research to medicine - Journal of Thrombosis and Haemostasis](https://www.jthjournal.org/cms/attachment/1bdae1c8-490a-4cdb-888e-484865ab48a1/JTH_1213_f1_lrg.jpg)
Factor XIII and the clotting of fibrinogen: from basic research to medicine - Journal of Thrombosis and Haemostasis
![David Steensma, MD on Twitter: "Paul Arnor Owren (1905-1990) in Oslo evaluated Mary in 1943 for menorrhagia. She'd been almost blind since age 3 after an episode of epistaxis/syncope (?retinal hypoxia). Owren David Steensma, MD on Twitter: "Paul Arnor Owren (1905-1990) in Oslo evaluated Mary in 1943 for menorrhagia. She'd been almost blind since age 3 after an episode of epistaxis/syncope (?retinal hypoxia). Owren](https://pbs.twimg.com/media/EMGU7KHVUAAJ7WE.jpg)
David Steensma, MD on Twitter: "Paul Arnor Owren (1905-1990) in Oslo evaluated Mary in 1943 for menorrhagia. She'd been almost blind since age 3 after an episode of epistaxis/syncope (?retinal hypoxia). Owren
![David Steensma, MD on Twitter: "Factor XIII, "fibrin stabilizing factor", was originally called Laki–Lorand factor after Hungarian-American biochemists Kalman Laki and Laszlo Lorand @NIH who proposed its existence in a 1948 @sciencemagazine David Steensma, MD on Twitter: "Factor XIII, "fibrin stabilizing factor", was originally called Laki–Lorand factor after Hungarian-American biochemists Kalman Laki and Laszlo Lorand @NIH who proposed its existence in a 1948 @sciencemagazine](https://pbs.twimg.com/media/EMGVDB6VUAAvGDF.jpg:large)
David Steensma, MD on Twitter: "Factor XIII, "fibrin stabilizing factor", was originally called Laki–Lorand factor after Hungarian-American biochemists Kalman Laki and Laszlo Lorand @NIH who proposed its existence in a 1948 @sciencemagazine
![Frontiers | Low α2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis Frontiers | Low α2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis](https://www.frontiersin.org/files/Articles/901286/fcvm-09-901286-HTML/image_m/fcvm-09-901286-g001.jpg)